BDRX
Biodexa Pharmaceuticals plc
stockNASDAQADR
midatech is a world leader in the design, synthesis and manufacture of biocompatible gold nanoparticles (gnps) with a core focus on therapeutics for diabetes and cancer. midatech has a strong pipeline of product candidates in clinical and pre-clinical development for the treatment of diabetes and various cancers. in 2012, midatech established midasol therapeutics lp, a strategic joint venture with monosol rx llc to focus on the development and commercialization, via partnering or licensing, of products primarily for the treatment of diabetes. midasol's lead product, midaform™ insulin pharmfilm, is a unique product for the oral delivery of insulin in diabetic patients and will enter phase ii clinical studies in 2014. these technologies are also being evaluated in the diabetes area by a major us pharmaceutical company. midatech's unique gnp technology enables the administration and targeted delivery of therapeutic compounds to specific cells and tissues. multiple drug molecules can b
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.63 | 2026-10-01 | -19.22% | 3.742 |
| 1M | 0.83 | 2026-09-08 | -38.49% | 8.676 |
| 3M | 2.60 | 2026-07-08 | -80.35% | 3.174 |
| 6M | 3.51 | 2026-04-08 | -85.44% | 1.782 |
| 1Y | 38.55 | 2025-10-08 | -98.67% | 1.700 |
| 2Y | 281.00 | 2024-10-08 | -99.82% | — |
| 5Y | 47,030.00 | 2023-03-27 | -100.00% | 1.172 |
Biodexa Pharmaceuticals plc (NASDAQ:BDRX) stock price today is $0.51, and today's volume is 72,775. BDRX is down 9.365% today. The 30 day average volume is 7.15M. BDRX market cap is $525,853 with 1.03M shares outstanding.